# Ixazomib In Combination With Cyclophosphamide And Dexamethasone for Newly Diagnosed AL Amyloidosis

> **NCT03236792** · PHASE1,PHASE2 · COMPLETED · sponsor: **Icahn School of Medicine at Mount Sinai** · enrollment: 28 (actual)

## Conditions studied

- AL Amyloidosis

## Interventions

- **DRUG:** Ixazomib
- **DRUG:** Cyclophosphamide
- **DRUG:** Dexamethasone

## Key facts

- **NCT ID:** NCT03236792
- **Lead sponsor:** Icahn School of Medicine at Mount Sinai
- **Sponsor class:** OTHER
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2017-06-12
- **Primary completion:** 2022-09-20
- **Final completion:** 2022-09-20
- **Target enrollment:** 28 (ACTUAL)
- **Last updated:** 2022-09-29

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03236792

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03236792, "Ixazomib In Combination With Cyclophosphamide And Dexamethasone for Newly Diagnosed AL Amyloidosis". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT03236792. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*